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ritis, thrombotic microangiopathies and transplant reje­
ction. In this review we discuss current evidence that 
complement activation contributes to progression of CKD, 
how complement could cause renal inflammation and 
whether complement inhibition would slow progression 
of renal disease.
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Core tip: Complement activation occurs in progressive 
chronic kidney disease and may contribute to the 
chronic inflammation that is characteristically found 
in the kidney. It is therefore possible that inhibiting 
complement activation would reduce inflammation, lead 
to reduced fibrosis and preservation of renal function.
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INTRODUCTION
Chronic kidney disease (CKD) is recognised worldwide 
as a major public health problem[1]. In 2007 the United 
Kingdom age-standardised prevalence of CKD stages 
3-5 was 8.5% (10.6% in females and 5.8% in males)[2] 
and similar prevalences have been described in other 
countries. In 2012 in the United Kingdom, the number 
of new patients requiring renal replacement therapy was 
6891, equating to 108 patients per million population, 
with diabetes and glomerulonephritis being the two 
most common diagnoses in incident dialysis patients. 
Although not all patients with CKD will progress to renal 
failure, all stages of CKD are associated with increased 
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Abstract
Chronic kidney disease (CKD) is common and the cause 
of significant morbidity and mortality. The replacement 
of functioning nephrons by fibrosis is characteristic of 
progressive disease. The pathways that lead to fibrosis 
are not fully understood, although chronic non­resolving 
inflammation in the kidney is likely to drive the fibrotic 
response that occurs. In patients with progressive CKD 
there is histological evidence of inflammation in the 
interstitium and strategies that reduce inflammation 
reduce renal injury in pre­clinical models of CKD. The 
complement system is an integral part of the innate 
immune system but also augments adaptive immune 
responses. Complement activation is known to occur in 
many diverse renal diseases, including glomeruloneph­
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morbidity and mortality[1]. 
Tubulointerstitial inflammation and fibrosis is a major 
factor in the progressive loss of renal function in most 
kidney diseases[3]. The process is complex due to the 
number of interacting pathways which ultimately result 
in the replacement of functioning nephrons with scar 
tissue. Cellular stress and injury induces an inflam-
matory and pro-fibrogenic response involving growth 
factors[4-6] and pro-inflammatory cytokines as well as 
activation of the renin-angiotensin system. This leads 
to a chronic inflammatory cell infiltrate, increasing 
numbers of activated fibroblasts (myofibroblasts) and 
excessive matrix deposition. There is evidence from 
preclinical models that the immune system is important 
in the development of renal fibrosis[7,8]. A component 
of the innate immune system that may be important in 
driving renal inflammation is the complement system, 
which can directly affect cell function and also influence 
the adaptive immune response.
COMPLEMENT SYSTEM
The complement system is a biochemical cascade made 
up of approximately 30 serum and membrane-bound 
proteins and represents a major part of the innate 
immune system. Complement was identified in the 
late 19th century by German scientist Paul Ehrlich as a 
heat-labile blood serum component with non-specific 
antimicrobial activity that “complements” other immune 
functions. As part of the innate immune system, the 
complement system responds rapidly to defend the 
host against a variety of invading microorganisms[9]. 
The complement system can also participate during 
the inductive phase of the acquired immune response 
by contributing to the recognition and presentation 
of non-self antigen, triggering antigen presenting cell 
activation, maturation and proliferation[10,11]. 
The primary location for biosynthesis of com-
plement is the liver. Although Erlich and Morgenroth 
suggested the liver as the main source of complement 
production in 1900, it was only confirmed in 1976 
by Alper et al[12] who described recipient to donor C3 
allotype conversion after liver transplantation. This 
is also supported by studies of hepatocyte cell fun-
ction[13]. In addition, evidence for extrahepatic synth-
esis of complement increased and it is now known 
that extrahepatic complement synthesis contributes 
approximately 10% of circulating C3. The alternative 
sites for complement production include epithelial cells, 
fibroblasts, lymphocytes and macrophages derived 
from different organs, including the kidney[14]. In the 
kidney, local complement production has been shown 
to occur at different sites along the nephron and may 
be further enhanced by the presence of cytokines and 
infiltrating immune cells during acute inflammation[15-17].
ACTIVATION OF THE COMPLEMENT 
SYSTEM
Activation of the complement cascade is triggered by 
one of three distinct pathways: the classical pathway, 
the alternative pathway and the mannose-binding 
lectin (MBL) pathway (Figure 1). All three pathways 
converge to cleave complement component C3, 
which subsequently initiates activation of the terminal 
complement pathway and formation of the membrane 
attack complex (MAC). The classical pathway is 
initiated by the activation of the C1 complex when C1q 
binds the Fc region of IgG or IgM. There is sequential 
cleavage of activation of C4 and C2, leading to the 
assembly of the classical pathway C3 convertase.
Activation of the alternative pathway is dependent 
on the spontaneous low level hydrolysis of the internal 
thioester bond of C3 to C3(H2O). C3(H2O) resembles 
C3b and can bind to factor B (FB). FB is activated by 
factor D forming the alternative pathway C3 convertase. 
The alternative pathway also amplifies the classical 
and lectin-binding pathways and is therefore critical for 
the full activity of complement. The third complement 
activation pathway, the lectin-binding pathway, is 
homologous to the classical pathway except that it is 
activated by the binding of a lectin to carbohydrates 
on microbial surfaces. The C3 convertase cleaves 
C3 resulting in assembly of the C5 convertase and 
sequential binding of C6, 7, 8 and 9 to form C5b-9, the 
membrane attack complex.
The main purpose of complement activation is 
to remove invading pathogenic organisms such as 
bacteria. This is achieved directly through the formation 
of the MAC or indirectly by opsonisation and stimulation 
of phagocytosis. Products of C3 and C4 activation on the 
surface of pathogens are recognised by the complement 
receptors CR1 and CR3 present on macrophages and 
neutrophils leading to phagocytosis of the opsonised 
target. Complement activation results in production of 
the small, biologically active anaphylatoxins, C3a and 
C5a. These readily diffusible complement components 
have a variety of functions, including chemotaxis and 
release of histamine from mast cells, mediated through 
binding to specific receptors[18]. These receptors, and 
also CRs1-4 (Table 1), are present on many immune 
cells and provide links between complement and the 
adaptive immune system[19,20].
The complement system contains proteins, both 
membrane bound and fluid phase, which regulate acti­
vation to prevent damage to host cells. They act by 
promoting decay of the convertase complexes, act as 
cofactors for the enzymatic degradation of the active 
proteins and by preventing the assembly of the MAC. 
The importance of these regulators is seen when their 
function is impaired, resulting in excessive complement 
activation and tissue injury.
COMPLEMENT ACTIVATION IN RENAL 
DISEASE
Complement activation is known to occur in immune 
mediated glomerular diseases (lupus nephritis, mem-
branous nephropathy and post-infectious glomerulo-
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Table 1  Properties of complement receptors
Receptor Alternative name(s) Location Specificity Role
CR1 CD35 Macrophages
Neutrophils
B-cells
Some T-cells
Renal epithelium
C3b
C4b
Binding of opsonised immune complexes for transport to phagocytes
CR2 CD21 B-cells
Some T-cells
Dendritic cells
Epithelia
C3d Link between innate and acquired immune response on B-cells
Presentation of immune complexes to B-cells
CR3 CD11b/18 Macrophages
Natural killer cells
Neutrophils
iC3b Cellular-extracellular matrix linkage
Promotes phagocytosis of opsonised complexes
CR4 CD11c/18 Macrophages
Neutrophils
iC3b
C3dg
Receptor for iC3b-opsonised particles
C3aR - Renal epithelium
Macrophages
C3a Mediation of inflammation
C5aR CD88 Neutrophils C5a
C1qR CD93 Leukocytes
Platelets
Monocytes
Neutrophils
C1q Up-regulation of phagocytic capacity
Protein chaperone
Adapted from Morgan et al[94] 1999.
Figure 1  Complement activation pathways. Complement activation is triggered via activation of either the alternative, classical or lectin pathways, all three of which 
converge to cleave central component C3. Briefly, activation of the alternative pathway occurs following the spontaneous hydrolysis of C3 to C3(H2O). C3(H2O) binds 
factor B (FB) to form C3bB which is then cleaved by FD leaving the C3bBb complex. C3bBb is stabilised by properdin to form the alternative pathway C3 convertase. 
C3 is subsequently cleaved to C3a and C3b to form the C5 convertase C3BbC3b. Activation of the classical complement pathway occurs when immunoglobulin-
bound antigens bind to and activate the C1 complex (consisting of C1qr2s2). Activated C1qr2s2 cleaves C4 to C4a and C4b. C4b becomes membrane-bound and 
binds to pro-enzyme C2, which is then cleaved to C2a and C2b fragments by C1s. C2a remains bound to C4b, forming the classical C3 convertase C4b2a. C3 is 
cleaved to C3a and C3b to form the C5 convertase C4b2aC3b. The lectin complement pathway is homologous to the classical pathway, with the exception that it 
is activated by the binding of lectin to microbial cell surface carbohydrates (mannose). Surface-bound lectin activates MBL-associated serine proteases (MASPs), 
which directly activate C3 and directly cleave C2 and C4. Activation of the terminal complement pathway occurs when the alternative and classical C5 convertases 
C3bBbC3b or C4b2aC3b cleave C5 in to C5a and C5b. C5b binds to C6 and C7, forming C5b67, which associates with an adjacent membrane. C5b67 then binds to 
C8 and multiple C9 molecules forming the transmembrane pore C5b-9, also known as the MAC. 1Denotes the anaphylatoxins C3a and C5a. Orange boxes highlight 
regulatory complement proteins. MBL: Mannose-binding lectin; MAC: Membrane attack complex; DAF: Decay accelerating factor; MCP: Membrane cofactor protein.
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COMPLEMENT ACTIVATION IN 
PRECLINICAL MODELS OF PROTEINURIA
Pre­clinical models have significantly contributed to our 
understanding of the role of complement in proteinuric 
disease. Aminoglycosides (puromycin and adriamycin) 
disrupt glomerular epithelial function leading to 
glomerulosclerosis, proteinuria and tubulointerstitial 
fibrosis in rodents. Induction of disease in complement 
deficient mice has shown that complement activation 
contributes to glomerulosclerosis and tubulointerstitial 
fibrosis and that activation occurs via the alternative 
pathway[36,37]. These studies have also demonstrated 
the important function of complement regulatory 
proteins in controlling complement activation, as their 
deficiency exacerbates injury[36]. Evidence from studies 
in both mice and rats suggests that both MAC[38] and 
the anaphylatoxins may be responsible for the damage 
that occurs[36,39].
Other pre-clinical models have also been used to 
investigate how complement influences the development 
of tubulointerstitial injury including a model of mesangio-
proliferative glomerulonephritis[40] and the remnant 
kidney model[41,42]. Disease severity is reduced if an 
intact complement system is absent. These models also 
allow testing of the potential for therapeutic targeting 
of complement. There is strong evidence that either 
complement depletion[43] or inhibition[40] can reduce the 
severity of proteinuria-related tubulointerstitial disease. 
There is the potential to target therapeutic complement 
inhibition at the tubular epithelium. A recombinant 
protein with an antibody portion directed at the tubular 
brush border linked to a complement inhibitor reduced 
interstitial injury and preserved renal function in rats 
with puromycin nephrosis[44].
COMPLEMENT ACTIVATION IN NON-
PROTEINURIC KIDNEY DISEASE
Less is known about the role of complement in non-
proteinuric renal disease. Unilateral ureteric obstruction 
(UUO), induced by ligation of one ureter, is the most 
commonly used preclinical model of progressive renal 
disease. The injury is characterised by the gradual 
development of interstitial inflammation and fibrosis, 
macrophage, T cell and fibroblast infiltration and eventual 
loss of functioning nephrons, closely resembling the 
pathology of chronic renal disease observed in patients. 
The first study to address the role of complement in UUO 
used rats deficient in C6 which are unable to assemble 
MAC. No difference was seen in disease severity in 
normal or C6 deficient animals, indicating no role for 
MAC in disease development[45].
Boor et al[46] found that interstitial fibrosis and 
macrophage infiltration were significantly reduced in C5 
deficient (C5-/-) mice after five days of UUO. Similarly, 
nephritis), atypical haemolytic uraemic syndrome and 
during antibody mediated rejection. However, what is 
less clear is whether complement activation contributes 
to the non-disease specific inflammation, tissue injury 
and fibrosis that are characteristic of progressive neph­
ropathies.
COMPLEMENT ACTIVATION IN CLINICAL 
PROTEINURIC DISEASE
The association between proteinuria, tubulointerstitial 
fibrosis and declining renal function is well established, 
however, the mechanism by which proteinuric glom-
erular disease casuses interstitial injury is uncertain. 
Complement proteins will be filtered when glomerular 
permselectivity is impaired and enter the tubular 
compartment. Complement activation products can 
be found in the urine of patients with a wide variety 
of proteinuric diseases; diabetic nephropathy, mem-
branous nephropathy, IgA nephropathy and focal seg-
mental glomerulosclerosis (FSGS)[21]. In some cases 
this may be due to spill over of complement activated 
in the glomerulus, however, complement activation 
products can be found in diseases where glomerular 
complement activation is not a major feature, for 
example diabetic nephropathy and FSGS[21,22]. This 
implies that complement is activated within the tubular 
compartment.
The tubular epithelium activates complement on 
its apical surface[23,24], which occurs primarily via the 
alternative pathway[25,26]. There are several explanations 
for this. It may be related to urinary pH[21] or ammonia 
production from stressed epithelial cells[27] directly 
activating C3. There may be enzymes with convertase-
like activity in the apical brush border of the proximal 
tubule which is also known to be relatively deficient in 
complement regulatory proteins[28]. Properdin, which 
stabilises the alternative pathway convertase binds to 
the glycosaminoglycans on the apical surface of tubular 
epithelium[26]. Factor H also binds but at a different 
site[29,30], suggesting a balance between complement 
activation and inhibition which may be disturbed in 
proteinuria as albumin reduces Factor H binding[31]. 
Whatever the explanation, proteinuria provides a source 
of complement proteins to a host cell surface which is 
unable to control activation.
Demonstrating that complement activation is the 
cause of tissue injury in clinical proteinuric disease is 
difficult. Mosolits et al[32], studying patients with protein-
uria, found a spatial and quantitative relationship 
between renal MAC deposition and inflammatory 
cell infiltrate and tubulointerstitial expansion. Urinary 
MAC concentrations are increased in proteinuric renal 
diseases. The concentration can relate to disease 
activity[33] although this is not always the case[34,35] and 
is further complicated when there is glomerular immune 
complex deposition.
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significant reductions in fibronectin, vimentin, platelet­
derived growth factor (PDGF)-B and PDGF-D mRNA 
were observed in C5-/- mice. A protective effect was 
also observed when UUO mice were treated with a 
C5aR antagonist. In a more recent study of UUO in 
C3 deficient mice there was a significant reduction in 
interstitial fibrosis and tubular atrophy in the absence 
of complement activation[47]. It is clear from the above 
animal studies that activation of C3 and C5 contribute 
to the development of progressive renal fibrosis during 
experimental obstructive nephropathy, however, the 
mechanism by which this occurs remains largely 
uncharacterised. There are no corresponding clinical 
studies to support these pre-clinical observations.
COMPLEMENT FUNCTION IN DIABETIC 
NEPHROPATHY
Although diabetic nephropathy is initially glomerular, 
progression of disease is associated with both glomerulo-
sclerosis and tubulointerstitial fibrosis. There is evidence 
that complement may be involved in susceptibility to 
and progression of diabetic nephropathy. The serum 
concentration of mannose-binding lectin is variable and 
determined by polymorphisms in the gene promoter 
and coding sequence. Higher MBL concentrations 
early after the onset of type 1 diabetes may predict 
the development of nephropathy many years later[48]. 
Serum MBL concentrations are higher in type 1 diabetics 
with albuminuria and overt nephropathy[49,50] although 
this does not appear to relate to genotype. The effect of 
MBL on the development of diabetic nephropathy has 
been studied in MBL deficient mice with streptozotocin 
induced diabetes. The absence of MBL retards the 
development of glomerular disease and albuminuria[51], 
although not in all mouse strains[52].
MAC can be detected in the glomeruli of the pa-
tients with diabetes. Deposition may be increased 
by the glycosylation and loss of function of CD59, an 
inhibitor of MAC assembly[53]. In diabetic disease there 
is differential regulation of complement genes in both 
the glomerulus and tubular compartment[54], suggesting 
a possible role for complement proteins synthesised 
within the kidney. In addition, complement activation 
may be involved in the coronary and renal vascular 
disease associated with diabetes[53,55] and again the MBL 
pathway may be involved[56].
POLYCYSTIC KIDNEY DISEASE
In patients with inherited cystic kidney disease cysts 
develop within the nephron disrupting normal renal 
structure and function. It is evident that inflammatory 
and fibrotic changes occur in renal tissue surrounding 
the cyst and this may in part be responsible for the 
loss of renal function that occurs. In mouse models 
of cystic kidney disease there is increased expression 
of complement genes in cyst epithelium, particularly 
C3, and also evidence of complement activation[57,58]. 
To investigate a role for complement in cystogenesis 
Cys1cpk/cpk polycystic kidney disease mice were crossed 
with C3 deficient mice which lack the main effector 
functions of complement[58]. Mice deficient in C3 deve­
loped fewer cysts and had reduced renal volume, 
suggesting that complement, possibly by modifying 
inflammation, has a role in cyst development. This 
is supported by studies of complement inhibition in 
two different animal models of cystic disease[59]. Com-
plement inhibition reduced kidney volume, cyst number 
and reduced the inflammatory infiltrate in tissue 
adjacent to cysts. Critically complement inhibition also 
preserved renal function.
Proteomic analysis of cyst fluid from patients with 
autosomal dominant polycystic kidney disease (ADPKD) 
identified complement proteins within the cysts[60]. 
Increased concentrations of complement proteins, 
including C3, Factor B and C9, can also be found in the 
urine and by immunostaining along the cyst epithelium, 
suggesting activation of the alternative pathway[59,61]. 
Song et al[62] described the pattern of gene expression in 
ADPKD kidneys. Complement genes were consistently 
up regulated suggesting that a proportion of the com-
plement proteins in the cyst fluid may be derived from 
local synthesis.
COMPLEMENT AND PROGRESSIVE LOSS 
OF TRANSPLANT FUNCTION
Complement is important at many stages during 
the course of a kidney transplant: complement poly-
morphisms may alter outcome after transplantation[63], 
complement gene expression is increased in pre-
implantation biopsies and this can predict outcome[64], 
complement has a role in the development of ischaemia 
reperfusion injury[65] and augments the alloimmune 
response[66]. All of these factors may impact upon long-
term transplant outcome, however it is the role of 
complement in antibody mediated rejection (AMR) that 
has generated most interest recently.
Antibody binding to graft endothelium will activate 
complement, initially via the classical pathway. Complement 
can then alter endothelial function to enhance thrombosis 
and leukocyte chemotaxis. When this occurs acutely, most 
frequently seen in pre-sensitised or ABO incompatible 
transplants, it can lead to rapid graft loss. The most 
compelling evidence that complement is important in 
acute AMR is the reported experience of complement 
inhibition with monoclonal anti-C5 in the treatment[67,68] or 
prevention of AMR[69].
The role of complement in chronic AMR, increas-
ingly recognised as a cause of graft failure, is less clear. 
When the classical pathway is activated C4 covalently 
binds the endothelium. It is degraded to limit activation 
leaving a biologically inert fragment, C4d, attached to 
the endothelium. This can persist in the glomerulus 
and peri-tubular capillaries and act as a biomarker of 
Fearn A et al . Complement in chronic kidney disease
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antibody binding to endothelium. Detection of C4d in a 
transplant biopsy is now routinely used in the diagnosis 
of AMR and when present predicts a poor long-term 
outcome. Antibody can directly affect endothelial 
function[70] and whether complement further contributes 
to injury is less clear. There is currently a trial ongoing 
(NCT01327573) to assess the efficacy of anti-C5 
treatment in treating chronic AMR which will answer this 
question.
EFFECT OF COMPLEMENT ON RENAL 
CELL FUNCTION
Complement activation, through generation of anaphy-
lotoxin and sub-lytic concentrations of MAC can alter 
cell function. This may be the mechanism by which 
complement influences the progression of renal disease 
(Figure 2). Complement activation by the alternative 
pathway and deposition of sub-lytic concentrations of 
MAC on tubular epithelial cells stimulates the synthesis 
and release of pro-inflammatory cytokines (including 
tumor necrosis factor α and interleukin 6)[71], reactive 
oxygen species[25] and increases the synthesis of matrix 
proteins[72]. Complement can also induce expression 
of major histocompatibility antigens on tubular cells, 
allowing these cells to drive T cell proliferative responses, 
potentially augmenting allo and autoimmunity[73].
Renal epithelial can also respond to the anaphy-
latoxins, expressing both C3a receptor (C3aR)[74] 
and C5aR[75]. Tubular cells exposed to C3a, possibly 
synthesised from the tubular cells themselves[76], increase 
collagen synthesis[74] and adopt a more mesenchymal 
phenotype[39]. Similar effects can be seen in tubular 
epithelial cells exposed to C5a. The effect of C3a and 
C5a on tubular cells may in part be indirect due to 
increased activation of transforming growth factor 
beta and other growth factors that can be induced by 
the anaphylatoxins[77]. In an attempt to mimic more 
physiological conditions, the tubular cell line HK2 was 
grown on a microfluidic device allowing flow across its 
apical membrane. When the medium contained normal 
human serum or C3a the cells underwent mesenchymal 
transition and migrated into the supporting basement 
membrane[78].
LOCAL RENAL COMPLEMENT 
SYNTHESIS
The first study to demonstrate that human renal 
proximal tubular epithelial cells synthesised and secreted 
complement component C3 in vitro was published by 
Brooimans et al[15] more than 20 years ago. It is now 
Tubular
lumen
Interstitium Peri­tubular
capillary
Infiltrating
leukocytes
Proteinuria
Transferrin
Lipoproteins
Albumin
Complement
C3
C3a C3b
C5a
C5b­9
C5a Interstitial
fibroblasts
Apoptosis
TGFb
C3
IL­1
IL­6
Chemokines
Matrix
Figure 2  Complement-mediated renal injury. Complement proteins can access the tubulointerstitial compartment from the tubular lumen, the circulation or due 
to local synthesis. Activation can injure and activate the tubular epithelium inducing the synthesis of pro-inflammatory and pro-fibrotic cytokines. This results in an 
increase in interstitial inflammatory cells and fibroblasts, finally resulting in the deposition of excess matrix proteins. TGFb: Transforming growth factor beta; IL-1: 
Interleukin 1.
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evident that resident renal cells, including tubular[79-82] 
and glomerular epithelial cells[16,83], mesangial cells[16,84,85] 
and endothelial cells[17] can synthesise many, if not all 
complement proteins[86]. Complement production is 
stimulated by pro-inflammatory cytokines and gene 
expression is increased in biopsies form patients with 
inflammatory glomerulonephritis[87], acute rejection[88] and 
chronic kidney disease[89]. Making use of polymorphisms 
in C3 it is possible to quantify the amount of protein 
produced from a transplanted kidney when the donor 
and recipient are mismatched for these polymorphisms. 
Renal derived C3 can contribute up to 10% of circulating 
C3 when the transplant is undergoing acute rejection[90].
Several pre­clinical studies have highlighted the 
importance of intrarenal synthesis of complement as an 
important mediator of local tissue. Renal complement 
production is increased in models of renal disease[91]. A 
strategy of renal syngenic or allogeneic transplantation 
in knockout mice can create a mouse which has a 
deficiency only in local complement synthesis. Appli-
cation of this strategy has demonstrated a role for 
local C3 synthesis in transplant rejection[66], ischaemic 
reperfusion injury[92] and tubulointerstitial injury in 
proteinuric disease[93].
CONCLUSION
Chronic, non-resolving inflammation drives fibrosis in 
the kidney leading to a progressive loss of renal function. 
Complement activation occurs in the kidney during the 
progression of a broad range of renal diseases and could 
contribute to the inflammatory environment in which 
fibrosis occurs. There is increasing from pre-clinical 
models that complement activation may be linked with 
fibrosis, with some evidence for this from clinical studies. 
However, further work is required to define the role of 
the complement system in clinical disease progression.
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